Markov Model
Cross-source consensus on Markov Model from 1 sources and 5 claims.
1 sources · 5 claims
Where it comes from
Other
Highlighted claims
- The analysis used a lifetime Markov model adapted from a previously published US cost-utility analysis of ICM in cryptogenic stroke. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
- The model discounted both costs and health effects at 3% per year. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
- The analysis followed ICER reference case guidance and used a lifetime horizon to capture costs and health outcomes. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
- The payer perspective assumed a mix of 60% public Medicare and 40% private commercial insurance, with private payer costs set to 125% of Medicare rates. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
- Unit costs were based on 2022 US Medicare national average payment rates inflated to 2025 values. — Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA